Predicting Treatment Response Based on RNA Expression in Large Datasets

Abstract

PD-L1 expression levels derived from >16,000 samples guided the selection of tumor types likely to benefit from pembrolizuamb monotherapy in clinical trials. Although not fail-proof, FDA approvals for most of the prioritized indications speak to the power of RNA expression profiling and the value of large genomic datasets.See related article by Ayers et al., p. 1564.